To investigate the effectiveness and the tolerability of a combined pure anti-inflammatory therapy not associated to antibiotics on reducing PSA levels.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
patients with a previous biopsy negative for prostate cancer and showing persisting level of PSA greater than 4ng/dl were recruited. The specimens of previous biopsy were classified as benign or showing inflammation. Eligible patients were divided into two equal groups. In group one were selected men with histological findings of inflammation at the previous prostatic biopsy, in group two patients without such findings. Men of both groups were treated for three months with the same pure anti-inflammatory scheme including nimesulide, serenoa repens, bromelain and quercetin. After treatment PSA levels were determined again. Independently by the second PSA determinations all patients underwent a second 16 core biopsy.
140 patients were enrolled. No adverse reactions were reported. Total PSA lowered from 7,3 ng/ml at baseline to 4,6 ng/ml (p<0,0001) after treatment in group one and from 7,2 ng/ml to 7 ng/ml (p=0,0005) in group two. Overall we diagnosed a prostate cancer at the second biopsy in 27 men among 140 (19,2%). The percentage of cancer at re-biopsy was 20% (14/70) in group one and 18,5% (13/70) in group two. We found no cancer at the second biopsy in cases of PSA reduction below 4 ng/ml in both groups.
Our protocol was very effective and safe in reducing PSA levels. The second biopsy failed to show PC in all patients with PSA lower than 4 ng/ml.
Urology. 2016 May 18 [Epub ahead of print]
Gallo Urology Centre, Via Santa Lucia 97, Naples 80132, Italy, Phone/fax+390817649530; mobile: +393389838481. Website: www.studiourologicogallo.it. Electronic address: .